This question was particularly important since HIVNET 012, a study conducted by NIAID-funded researchers in Uganda, showed that in a population of HIV-infected pregnant women who do not receive any antiretroviral therapy, nevirapine reduces the risk of HIV transmission by nearly 50 percent compared with a very short course of zidovudine (AZT).